1don MSN
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...
Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle ...
The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new ...
Chemotherapy drugs that target cancer cells without damaging normal cells remain one of the key goals of precision medicine in cancer treatment. The challenge is designing drugs that do this ...
Nurix advances CLL therapy with NX-5948 showing 83% response, 22.1-month PFS, $680M cash, and $3B risk-adjusted sales ...
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...
Government regulations affect drug development, often prolonging the process, but they ensure safety and efficacy to protect ...
Memantine, a long-approved and cost-effective drug used to treat Alzheimer’s disease, could also benefit patients with sickle cell anemia in the future. Initial clinical data from an international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results